Gyre Therapeutics, Inc.

GYRE

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001124105

A

strongest fifth of 369 graded peers in healthcare

rank 27 of 369; percentile 7.1; sampling error 2.5 points; lower is stronger

A B C D E

A, the bull



Scoreboard	
Profitability	C percentile 51.1
Solvency	B percentile 23.2
Growth and financing	A/B percentile 21.4
Reliability	0.87 AUC filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$120M to $591M assets total assets $166.1M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered; fortress balance sheet not computable: distress
Inputs computable	7 of 14
Graded from	filings received through Mar 13, 2026 242 days before the rescan; latest periodic filing 10-Q received Nov 6, 2026
Last close	$4.63 2026-11-09; market equity $534.5M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 13, 2026

In this section, unless otherwise specified, references to "we," "our," "us" and "our company" refer to Gyre Therapeutics, Inc. and our majority indirectly owned subsidiary, Beijing Continent Pharmaceuticals Co., Ltd. (d/b/a Gyre Pharmaceuticals Co., Ltd.) ("Gyre Pharmaceuticals"). We are a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. We operate through our majority indirectly owned subsidiary, Gyre Pharmaceuticals, in the PRC, and through our U.S. operations headquartered in San Diego, California.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 51.1						
Gross profitability	66.9%	32.3%		12.9	365	2025-12-31
Return on invested capital	not computable	9.3%				
pretax income must exceed the validity floor and imply a 0%-100% tax rate						

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	6.1%	(6.6%)		89.4	800	2025-12-31
Gross margin stability, five years	not computable	2.8 pts				
five annual gross margins are required; found 3						
Solvency, sleeve percentile 23.2						
Twelve-month failure probability	not computable	0.08%				
four consecutive discrete net-income quarters are required; found 4						
Altman Z double-prime	7.11	(0.35)		13.8	745	2025-12-31
Net debt to EBITDA	not computable	1.82x				
EBITDA must exceed $100,000						
Interest coverage	not computable	(4.51x)				
latest aligned inputs end 2015-12-31; latest annual assets end 2025-12-31						
Current ratio	5.60x	2.95x		32.6	826	2025-12-31
Growth and financing, sleeve percentile 21.4						
Revenue growth, three-year compound	not computable	10.1%				
four consecutive annual observations are required						
Free cash flow growth, three-year compound	not computable	11.0%				
four consecutive annual FCF observations are required; found 12						
Reinvestment rate	477.3%	37.1%		5.8	105	2025-12-31
Asset growth, three years	25.2%	2.2%		18.0	694	2025-12-31
Net share issuance, one year	3.6%	2.5%		40.3	629	2026-03-02

Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Fortress balance sheet	cash minus debt is 1,544,000 USD; Altman Z is not used

Among 369 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
22	Vericel Corp. (VCEL)	5.7	A	
23	Crispr Therapeutics AG (CRSP)	6.0	A	
24	Ideaya Biosciences, Inc. (IDYA)	6.2	A	
25	AtriCure, Inc. (ATRC)	6.5	A	
26	United Therapeutics Corp. (UTHR)	6.8	A	
27	Gyre Therapeutics, Inc. (GYRE)	7.1	A	fortress balance sheet
28	Hims & Hers Health, Inc. (HIMS)	7.3	A	
29	Viridian Therapeutics, Inc.\DE (VRDN)	7.6	A	dilution, fortress balance sheet
30	iRhythm Holdings, Inc. (IRTC)	7.9	A	fortress balance sheet
31	Veracyte, Inc. (VCYT)	8.2	A	
32	Alkermes plc. (ALKS)	8.4	A	

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

What the price implies

at the 2026-11-09 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(5.4%)	(1.9%)	47
Distance from 52-week high	(46.9%)	(27.5%)	30
EBIT to enterprise value	2.3%	(1.5%)	62
Free cash flow yield	(0.03%)	(1.0%)	55
Book value to price	0.20	0.27	41
Sales to price	0.22	0.29	41
Composite equity issuance, five years	219.6%	20.8%	91
Relative strength against the sector, log excess return	(0.22)	(0.19)	47

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	fail
Operating cash flow exceeds net income	fail
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$41.6M
Operating cash flow, four quarters	-$6.3M
Months of runway	78.9
Days since last periodic filing	4 (10-Q received Nov 6, 2026)
Median daily dollar volume, 63 sessions	$730,489

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$116.6M	2025-12-31	2026-03-13	10-K	26-106251
2	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$5.4M	2025-12-31	2026-03-13	10-K	26-106251
3	assets	us-gaap:Assets	$166.1M	2025-12-31	2026-03-13	10-K	26-106251
4	operating income	us-gaap:OperatingIncomeLoss	-$7.5M	2014-12-31	2016-03-09	10-K	16-498295
5	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$29.1M	2014-12-31	2015-03-16	10-K	15-093871
6	income tax	us-gaap:IncomeTaxExpenseBenefit	$3.5M	2014-12-31	2015-03-16	10-K	15-093871
7	total debt	us-gaap:LongTermDebt	$0	2014-12-31	2015-03-16	10-K	15-093871
8	book equity	us-gaap:StockholdersEquity	-$109.4M	2014-12-31	2017-03-08	10-K	17-003722
9	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$1.5M	2014-12-31	2017-03-08	10-K	17-003722
10	total debt	us-gaap:LongTermDebt	$1.1M	2013-12-31	2014-03-14	10-K	14-099974
11	book equity	us-gaap:StockholdersEquity	-$103.0M	2013-12-31	2016-03-09	10-K	16-498295
12	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$2.8M	2013-12-31	2016-03-09	10-K	16-498295
13	net income	us-gaap:NetIncomeLoss	$9.9M	2025-12-31	2026-03-13	10-K	26-106251
14	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$1.0M	2025-12-31	2026-03-13	10-K	26-106251
15	assets	us-gaap:Assets	$125.4M	2024-12-31	2026-03-13	10-K	26-106251
16	current assets	us-gaap:AssetsCurrent	$102.4M	2025-12-31	2026-03-13	10-K	26-106251
17	current liabilities	us-gaap:LiabilitiesCurrent	$18.3M	2025-12-31	2026-03-13	10-K	26-106251
18	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$68.4M	2025-12-31	2026-03-13	10-K	26-106251

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

19	operating income	us-gaap:OperatingIncomeLoss	$11.5M	2025-12-31	2026-03-13	10-K	26-106251
20	book equity	us-gaap:StockholdersEquity	$106.0M	2025-12-31	2026-03-13	10-K	26-106251
21	liabilities	us-gaap:Liabilities	$23.9M	2025-12-31	2026-03-13	10-K	26-106251
22	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$680,000	2014-12-31	2016-03-09	10-K	16-498295
23	operating income	us-gaap:OperatingIncomeLoss	-$13.8M	2015-12-31	2017-03-08	10-K	17-003722
24	interest expense	us-gaap:InterestExpense	$1.5M	2015-12-31	2017-03-08	10-K	17-003722
25	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$105.8M	2024-12-31	2026-03-13	10-K	26-106251
26	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$113.5M	2023-12-31	2025-03-17	10-K	25-040279
27	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$7.3M	2021-12-31	2022-03-31	10-K	22-012877
28	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$1.2M	2025-12-31	2026-03-13	10-K	26-106251
29	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$2.5M	2025-12-31	2026-03-13	10-K	26-106251
30	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$14.4M	2025-12-31	2026-03-13	10-K	26-106251
31	income tax	us-gaap:IncomeTaxExpenseBenefit	$4.6M	2025-12-31	2026-03-13	10-K	26-106251
32	current assets	us-gaap:AssetsCurrent	$64.8M	2024-12-31	2026-03-13	10-K	26-106251
33	current liabilities	us-gaap:LiabilitiesCurrent	$19.5M	2024-12-31	2026-03-13	10-K	26-106251
34	assets	us-gaap:Assets	$116.5M	2023-12-31	2025-03-17	10-K	25-040279
35	assets	us-gaap:Assets	$84.8M	2022-12-31	2024-03-27	10-K	24-037242
36	shares outstanding	dei:EntityCommonStockSharesOutstanding	96,963,611	2026-03-02	2026-03-13	10-K	26-106251
37	shares outstanding	dei:EntityCommonStockSharesOutstanding	93,612,442	2025-03-07	2025-03-17	10-K	25-040279

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.